Take Solutions Limited has officially announced the launch of a ₹50 million innovation fund through a regulatory filing under SEBI Regulation 30, targeting startups in artificial intelligence, deep technology, and digital health sectors. The initiative represents a strategic pivot towards enabling next-generation, technology-led business models while positioning the company to capitalize on India's projected $400-500 billion health and wellness market opportunity.

Regulatory Filing and Fund Structure

The company filed the announcement with both BSE and NSE exchanges, providing formal disclosure of the innovation fund launch. The fund carries an initial corpus commitment of Rs. 50 million (Rs. 5 crore) and focuses on early- and growth-stage companies leveraging data, AI, and scientific innovation to transform healthcare delivery and diagnostics.

Strategic Investment Focus Areas

The Innovation Fund will deploy capital across four key segments designed to address critical gaps in healthcare access, affordability, and efficiency:

• AI & Data Intelligence: Supporting startups developing AI-driven diagnostics, predictive analytics platforms, and scalable SaaS solutions
• Longevity & Bio-Convergence: Investing in genomics, cellular health, and age-reversal technologies
• Digital Health Platforms: Backing remote monitoring, wearable technologies, and real-time health data ecosystems
• Technology Infrastructure: Enabling platforms that enhance efficiency, compliance, and scalability across knowledge-led industries

Market Opportunity and Value Creation

According to Mr. Parmeshvar Dhangare, Director of Take Solutions, the fund aims to partner with visionary entrepreneurs solving complex global challenges. The investment thesis centers on the convergence of biology and technology driving the next wave of global value creation, particularly given that chronic diseases account for nearly 60% of deaths globally.

The fund will provide strategic support beyond capital, including domain expertise in life sciences and supply chain management, institutional partnerships across clinical and regulatory networks, and access to established go-to-market channels. This integrated approach is designed to accelerate commercialization and enhance scalability for portfolio companies.

Digital Health Platform Launch

Complementing the innovation fund, Take Solutions has launched Take.Health, an AI-driven digital health platform that converts lifestyle and medical data into personalized insights. The platform targets India's rapidly growing digital population and addresses opportunities across consumer wellness and enterprise health segments, enabling scalable, recurring revenue streams aligned with the Government of India's vision of leveraging AI for inclusive growth.

Take solutions Limited has announced the appointment of new statutory auditors following a board meeting held on March 26, 2026. The decision addresses a casual vacancy in the auditor position and requires shareholder approval to become effective.

Board Meeting Outcomes

The company's Board of Directors convened on March 26, 2026, from 06:30 PM to 07:00 PM to deliberate on key matters. Based on the Audit Committee's recommendation, the board approved the appointment of M/s. A. Raghavendra Rao & Associates, Chartered Accountants as the company's new statutory auditors.

Auditor Transition Details

The appointment fills a casual vacancy created by the resignation of M/s. Venkat and Rangaa LLP, Chartered Accountants (FRN: 004597S and PRC No.: 015938). The transition ensures continuity in the company's statutory audit functions while maintaining compliance with regulatory requirements.

New Auditor Profile

M/s. A. Raghavendra Rao & Associates brings substantial experience to TAKE Solutions. The firm was established in 1986 as a partnership providing comprehensive audit and assurance services. Their service portfolio includes statutory audits, tax audits, internal and concurrent audits, accounting and compliance services, and management advisory services.

Regulatory Compliance

The appointment follows Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in accordance with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company has disclosed that there are no relationships between the new auditors and the company's directors, ensuring independence in the audit process.

The board meeting documentation was digitally signed by Director Parmeshvar Dhangare (DIN: 11410125), confirming the formal approval of the auditor appointment subject to shareholder consent. The company has notified both BSE Limited and National Stock Exchange of India Limited about this development as per regulatory requirements.